Neurocrine’s Strong Financial Performance and Growth Prospects Drive Buy Rating

Analyst Ami Fadia from Needham maintained a Buy rating on Neurocrine and increased the price target to $161.00 from $139.00.

Ami Fadia has given his Buy rating due to a combination of factors that highlight Neurocrine’s strong financial performance and promising growth prospects. The company reported a higher-than-expected GAAP EPS, driven by a significant revenue beat, despite increased SG&A and R&D expenses. Notably, sales of Crenessity exceeded expectations, and Ingrezza sales slightly surpassed projections, indicating robust demand for these products.
Furthermore, the management’s strategic adjustments, such as narrowing Ingrezza’s guidance and raising SG&A guidance, suggest a proactive approach to managing financial targets. The anticipated continued strong uptake of Crenessity and the expansion of Ingrezza’s coverage are expected to drive volume growth in the upcoming quarters, despite facing some pricing challenges. Overall, the momentum in executing in-market products and advancing the pipeline supports the optimistic outlook for Neurocrine’s stock.